受天然配体启发的肽用于c-MET靶向PET探针开发
本研究基于肝细胞生长因子(HGF)N端及kringle 1结构域设计三种c-MET靶向肽,经DOTA偶联和68Ga标记后,在体外和体内评估其作为PET探针的性能。其中[68Ga]Ga-DOTA-A-M8对c-MET亲和力高(IC50=5.43 nM),在HCT-116荷瘤模型中显示特异性高摄取,30分钟肿瘤摄取为2.91±0.20%ID/g,主要通过肾-膀胱途径清除,结论认为基于天然配体开发PET探针是有效且可推广的策略。
要点
- 基于HGF的NK1结构域设计三种c-MET靶向肽并经68Ga标记。
- [68Ga]Ga-DOTA-A-M8对c-MET亲和力IC50=5.43 nM,在HCT-116细胞显示特异性高摄取。
- 小动物PET/CT中[68Ga]Ga-DOTA-A-M8在120分钟内清晰显影肿瘤,主要通过肾-膀胱途径清除。
核心结论
- 本研究成功开发了一种新型c-MET靶向PET探针[68Ga]Ga-DOTA-A-M8,具有高肿瘤靶向能力和特异性。
- 作者认为基于天然配体开发PET探针是有效且可推广的策略。
研究设计与样本
- 从HGF的N端和kringle 1结构域(NK1:32-207氨基酸残基)设计三种c-MET靶向肽,与DOTA偶联后用[68Ga]GaCl3标记,得到[68Ga]Ga-DOTA-K1、[68Ga]Ga-DOTA-A-C5和[68Ga]Ga-DOTA-A-M8三种探针,并进行体外和体内评估。
主要发现
- 三种PET探针中,[68Ga]Ga-DOTA-A-M8对c-MET亲和力高(IC50=5.43 nM),在c-MET高表达HCT-116细胞中显示特异性和高摄取。
- 小动物PET/CT成像用[68Ga]Ga-DOTA-A-M8在120分钟内清晰显示肿瘤,对比度良好。
- PET图像定量分析显示,注射后30分钟[68Ga]Ga-DOTA-A-M8在HCT-116模型的肿瘤摄取为2.91±0.20%ID/g。
- 生物分布研究显示,注射后30分钟HCT-116肿瘤摄取在正常组为2.84±0.07%ID/g,在阻断组为0.54±0.09%ID/g。
- 注射后30分钟肿瘤/肌肉、肿瘤/血液和肿瘤/肝脏比值分别为3.60±1.09、1.48±0.24和2.48±0.28;探针主要通过肾-膀胱途径清除。
关键数值与推荐
- [68Ga]Ga-DOTA-A-M8对c-MET的IC50=5.43 nM。
- 注射后30分钟HCT-116肿瘤摄取:正常组2.84±0.07%ID/g vs 阻断组0.54±0.09%ID/g。
- 注射后30分钟肿瘤/肌肉、肿瘤/血液和肿瘤/肝脏比值分别为3.60±1.09、1.48±0.24和2.48±0.28。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Native ligand-derived peptides have significantly advanced the development of targeting ligands in radiopharmaceutical discovery and design. Herein, we report the first attempt to develop novel mesenchymal-epithelial transition factor (c-MET) targeted peptide positron emission tomography (PET) probes based on the endogenous biomolecule, hepatocyte growth factor (HGF). METHODS: Three c-MET targeted peptides were designed from the N-terminal and kringle 1 domain (NK1: 32-207 amino acid residues) of HGF. Then they were conjugated with chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and radiolabeled with [68Ga]GaCl3. The resulted [68Ga]Ga-labelled probes, [68Ga]Ga-DOTA-K1, [68Ga]Ga-DOTA-A-C5, and [68Ga]Ga-DOTA-A-M8 were evaluated in vitro and in vivo. RESULTS: Among three PET probes, [68Ga]Ga-DOTA-A-M8 exhibited a high affinity for c-MET (IC50 = 5.43 nM) and demonstrated specific and high uptake in c-MET highly expressing HCT-116 cells. Small animal PET/CT imaging clearly visualized the tumor with good contrast using [68Ga]Ga-DOTA-A-M8 over 120 min. Quantitative analysis of PET images revealed tumor uptake of [68Ga]Ga-DOTA-A-M8 at 30 min post-injection was 2.91 ± 0.20%ID/g in HCT-116 models. The probe was mainly cleared out through the kidney-bladder pathway. Biodistribution study showed HCT-116 tumor uptake of 2.84 ± 0.07%ID/g and 0.54 ± 0.09%ID/g in the normal and blocking mice group, respectively, at 30 min post-injection. The tumor-to-muscle, tumor-to-blood and tumor-to-liver ratios were 3.60 ± 1.09, 1.48 ± 0.24 and 2.48 ± 0.28, respectively, at 30 min. CONCLUSION: A novel c-MET-targeting PET probe, [68Ga]Ga-DOTA-A-M8, has been successfully developed in this study. It demonstrates high tumor-targeting capability and specificity. This study highlights developing PET probes based on native ligands is a powerful and generalizable strategy.
引用
- Luo R, Tan B, Zhang Y, et al. Native Ligand-Inspired peptides for c-MET targeted PET probes development. Eur J Nucl Med Mol Imaging. 2025. PMID: 40522466. doi:10.1007/s00259-025-07403-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。